skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: Oxford Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age
103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age
Material Type:
Artigo 		Adicionar ao Meu Espaço

103P Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age

Zovato, S. ; Griguolo, G. ; Agata, S. ; Tognazzo, S. ; Dieci, M.V. ; Matricardi, L. ; Crivellari, G. ; Miglietta, F. ; Alducci, E. ; Moserle, L. ; Conte, P.F. ; Montagna, M. ; Guarneri, V.

Annals of oncology, 2021-09, Vol.32, p.S400-S401 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
2
105P A model of workflow for radiomics signature of stage III non-small cell lung cancer (NSCLC) patients (pts)
105P A model of workflow for radiomics signature of stage III non-small cell lung cancer (NSCLC) patients (pts)
Material Type:
Artigo 		Adicionar ao Meu Espaço

105P A model of workflow for radiomics signature of stage III non-small cell lung cancer (NSCLC) patients (pts)

Ferro, A. ; Pasello, G. ; Scagliori, E. ; Caumo, F. ; Costa, M. ; Frega, S. ; Sepulcri, M. ; Bonanno, L. ; Rea, F. ; Guarneri, V. ; Gennaro, G.

Annals of oncology, 2022-04, Vol.33, p.S79-S80 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
1081O_PRPROFESSIONAL BURNOUT IN EUROPEAN YOUNG ONCOLOGISTS: A EUROPEAN SURVEY CONDUCTED BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) YOUNG ONCOLOGISTS COMMITTEE
1081O_PRPROFESSIONAL BURNOUT IN EUROPEAN YOUNG ONCOLOGISTS: A EUROPEAN SURVEY CONDUCTED BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) YOUNG ONCOLOGISTS COMMITTEE
Material Type:
Artigo 		Adicionar ao Meu Espaço

1081O_PRPROFESSIONAL BURNOUT IN EUROPEAN YOUNG ONCOLOGISTS: A EUROPEAN SURVEY CONDUCTED BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) YOUNG ONCOLOGISTS COMMITTEE

Banerjee, S ; Califano, R ; Corral, J ; De Azambuja, E ; De Mattos-Arruda, L ; Guarneri, V ; Hutka, M ; Jordan, K ; Martinelli, E ; Mountzios, G ; Ozturk, M.A ; Petrova, M ; Postel-Vinay, S ; Preusser, M ; Qvortrup, C ; Strijbos, M ; Volkov, N.M ; Olmos, D

Annals of oncology, 2014-09, Vol.25 (suppl_4) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível

Citações Citado por
4
1157P Diagnostic therapeutic pathway (DTP) of early stage non-small cell lung cancer (eNSCLC): A real-world focus on EGFR status detection in resected patients (pts)
1157P Diagnostic therapeutic pathway (DTP) of early stage non-small cell lung cancer (eNSCLC): A real-world focus on EGFR status detection in resected patients (pts)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1157P Diagnostic therapeutic pathway (DTP) of early stage non-small cell lung cancer (eNSCLC): A real-world focus on EGFR status detection in resected patients (pts)

Pasello, G. ; Lorenzi, M. ; Pretelli, G. ; Pezzuto, F. ; Comacchio, G. ; Buja, A. ; Bonanno, L. ; Guarneri, V. ; Conte, P.F. ; Rea, F. ; Calabrese, F.

Annals of oncology, 2021-09, Vol.32, p.S933-S933 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
5
119P Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single-center real-world scenario over 10 years
119P Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single-center real-world scenario over 10 years
Material Type:
Artigo 		Adicionar ao Meu Espaço

119P Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single-center real-world scenario over 10 years

Ferro, A. ; Sepulcri, M. ; Schiavon, M. ; Scagliori, E. ; Gennaro, G. ; Costa, M. ; Bonanno, L. ; Frega, S. ; Dal Maso, A. ; Calabrese, F. ; Rea, F. ; Caumo, F. ; Guarneri, V. ; Pasello, G.

Annals of oncology, 2022-04, Vol.33, p.S87 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
1221P Surgically resected superior sulcus (SS) non-small cell lung cancer (NSCLC) after induction chemo (C)- and radiotherapy (R): A focus on the immune microenvironment (IM)
1221P Surgically resected superior sulcus (SS) non-small cell lung cancer (NSCLC) after induction chemo (C)- and radiotherapy (R): A focus on the immune microenvironment (IM)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1221P Surgically resected superior sulcus (SS) non-small cell lung cancer (NSCLC) after induction chemo (C)- and radiotherapy (R): A focus on the immune microenvironment (IM)

Pavan, A. ; Fortarezza, F. ; Pezzuto, F. ; Polverosi, R. ; Evangelista, L. ; Frega, S. ; Bonanno, L. ; Guarneri, V. ; Rea, F. ; Conte, P.F. ; Calabrese, F. ; Pasello, G.

Annals of oncology, 2020-09, Vol.31, p.S797-S797 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)
129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)
Material Type:
Artigo 		Adicionar ao Meu Espaço

129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)

Bonanno, L. ; Zulato, E. ; Del Bianco, P. ; Boscolo Bragadin, A. ; Attili, I. ; Pavan, A. ; Nardo, G. ; Dal Maso, A. ; Ferro, A. ; Frega, S. ; Pasello, G. ; M. Fassan ; Calabrese, F. ; Guarneri, V. ; Indraccolo, S.

Annals of oncology, 2022-09, Vol.33, p.S596 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial
129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial

Dieci, M.V. ; Griguolo, G. ; Bisagni, G. ; Musolino, A. ; Spazzapan, S. ; Moretti, G. ; Schiavi, F. ; Pinato, C. ; Vernaci, G.M. ; Giarratano, T. ; Urso, L. ; Tosi, A. ; Magni, G. ; Lo Mele, M. ; De Salvo, G.L. ; Rosato, A. ; Guarneri, V. ; Conte, P.F.

Annals of oncology, 2021-09, Vol.32, p.S414-S414 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
9
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
Material Type:
Artigo 		Adicionar ao Meu Espaço

1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)

Maso, A. Dal ; Ferro, A. ; Lorenzi, M. ; Polo, V. ; Scattolin, D. ; Del Conte, A. ; Scoccia, E. ; Frega, S. ; Bonanno, L. ; Indraccolo, S. ; Calabrese, F. ; Guarneri, V. ; Conte, P.F. ; Pasello, G.

Annals of oncology, 2020-09, Vol.31, p.S886-S886 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
10
140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial

Guarneri, V. ; Dieci, M.V. ; Griguolo, G. ; Pare Brunet, L. ; Marin, M. ; Miglietta, F. ; Bottosso, M. ; Giorgi, C.A. ; Blasco, P. ; Castillo, O. ; Galván, P. ; Jares, P. ; Puig-butille, J.A. ; Vivancos, A. ; Villagrasa Gonzalez, P. ; Parker, J. ; Perou, C.M. ; Conte, P.F. ; Prat, A.

Annals of oncology, 2022-09, Vol.33, p.S603 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2001  (5)
  2. 2001Até2008  (5)
  3. 2009Até2014  (5)
  4. 2015Até2018  (25)
  5. Após 2018  (61)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.